<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757029</url>
  </required_header>
  <id_info>
    <org_study_id>NETADHD</org_study_id>
    <nct_id>NCT00757029</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)</brief_title>
  <acronym>NETADHD</acronym>
  <official_title>Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The noradrenergic system plays a known role in attentional systems and suspected causal role
      in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as
      a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that
      norepinephrine transporter polymorphism is associated with responses and adverse effects of
      OROS-methylphenidate in treatment of ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Korean ADHD Rating scale-parent version (KARS)</measure>
    <time_frame>baseline,1,2,4,8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barkely side effect rating scale</measure>
    <time_frame>1,2,4,8weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <condition>Methylphenidate</condition>
  <condition>Pharmacogenetics</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>norepinephrine transporter polymorphism,</intervention_name>
    <description>OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism</description>
    <arm_group_label>open label</arm_group_label>
    <other_name>OROS methylphenidate (Concerta) monopharmacotherapy</other_name>
    <other_name>dose : 18-54mg</other_name>
    <other_name>duration : 8 weeks</other_name>
    <other_name>genotyping : norepinephrine transporter (SLC6A2) polymorphism</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADHD

          -  Physically healthy

        Exclusion Criteria:

          -  Neurological illness

          -  Concurrent additional psychiatric treatment

          -  &lt; IQ 70

          -  Psychotic disorder

          -  Major mood disorder needed other psychiatric medication

          -  Significant suicidal ideation

          -  Pervasive developmental disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD,</keyword>
  <keyword>norepinephrine transporter</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

